2 Dec 2015 11:19
2 December 2015
LSE: VER
Vernalis Results of Annual General Meeting
Resolutions
Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.
All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.
Resolution | For (including discretionary votes)* | Against* | Withheld | ||
Ordinary Resolutions (requires 50% majority) | |||||
1. That the audited accounts and related reports of the directors and auditors for the 18 month period ended 30 June 2015 be received | 391,016,343 | (99.99 %) | 778 | (0.01 %) | 2,250 |
2. That the remuneration report contained within the report and accounts for the 18 month period ended 30 June 2015 be approved | 377,719,542 | (97.07 %) | 11,414,741 | (2.93 %) | 1,885,088 |
3. That Dr Fellner be re-elected as a director | 389,132,501 | (99.99 %) | 2,775 | (0.01 %) | 1,884,095 |
4. That Ms Ferguson be re-elected as a director | 389,132,488 | (99.99 %) | 3,218 | (0.01 %) | 1,883,665 |
5. That Dr Gilham be re-elected as a director | 391,013,979 | (99.99 %) | 2,405 | (0.01 %) | 2,987 |
6. That Ms Schoenberg be re-elected as a director | 391,012,523 | (99.99 %) | 3,184 | (0.01 %) | 3,664 |
7. That Mr Sheail be re-elected as a director | 391,013,122 | (99.99 %) | 3,281 | (0.01 %) | 2,968 |
8. That PricewaterhouseCoopers LLP be reappointed auditors and the directors be authorised to determine their remuneration | 384,378,942 | (98.30 %) | 6,637,564 | (1.70 %) | 2,865 |
9. That the directors be authorised to allot shares | 391,003,076 | (99.99 %) | 13,502 | (0.01 %) | 2,793 |
Special Resolutions (requires 75% majority) | |||||
10. That the directors be authorised to disapply pre-emption rights | 391,000,159 | (99.99 %) | 14,814 | (0.01 %) | 4,398 |
11. That a General Meeting, other than an Annual General Meeting, may be called on not less than 14 clear days' notice | 391,012,985 | (99.99 %) | 4,541 | (0.01 %) | 1,845 |
*NB: A vote withheld is not a vote in law and, is not counted in the calculation of the votes for or against a resolution. Therefore, the percentage of votes cast excludes withheld votes
On 2 December 2015, there were 445,116,047 Vernalis plc ordinary shares in issue. Shareholders are entitled to one vote per share held.
The full text of each resolution passed at the Annual General Meeting held earlier today, Wednesday 2 December 2015, is set out in the Notice of Annual General Meeting which is available for viewing on the Company's website at www.vernalis.com.
-- ends -
Enquiries:
Vernalis: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Canaccord Genuity Limited (Nominated Adviser): | +44 (0) 20 7523 8350 |
Dr Julian Feneley Henry Fitzgerald-O'Connor Emma Gabriel
| |
Shore Capital (Joint Broker): | +44 (0)20 7408 4090 |
Bidhi Bhoma Toby Gibbs
| |
FTI Consulting: | +44 (0) 20 3727 1000 |
Ben Atwell Simon Conway Stephanie Cuthbert |
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra™ XR targeting the US prescription cough cold market; MOXATAG®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adult and paediatric patients 12 years of age or older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.
For further information about Vernalis, please visit www.vernalis.com